NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

NCT07433062

SuspendedPhase 1

Sponsor: AstraZeneca

Conditions: Type 2 Diabetes Mellitus

Interventions: AZD6793, AZD6793 Placebo

Countries: Germany

The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Physician-diagnosis of T2DM
* On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening.
* stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening
* HbA1c (Hemoglobin A1c) ≤ 8.5% at screening
* Body Mass Index (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening.

Exclusion Criteria:

* Physician diagnosis of type 1 diabetes.
* History of any clinically important disease or disorder.
* History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease
* History of Human immunodeficiency viruses (HIV) infection or a positive HIV test.
* History of prior episode(s) of lactic acidosis.

Locations (1)

Neuss, Germany